An object of the present invention is to provide an intestinal-environment-improving agent. The object can be achieved by an intestinal-environment-improving agent including an acacia bark extract.

An object of the present invention is to provide an intestinal-environment-improving agent. The object can be achieved by an intestinal-environment-improving agent including an acacia bark extract.

A water-soluble microencapsulated cannabinoid powder consisting essentially of a cannabinoid composition and at least one gum Acacia, and a method of making the same are provided.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.

The present disclosure describes products formulated to inhibit respiratory conditions and symptoms in animals, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a direct-fed microbial composition, at least one phytogenic compound, and/or at least one vitamin. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine or cattle at risk of developing, or already afflicted with, a respiratory condition. Inhibition of respiratory stress can reduce mortality rates and medication administration relative to animals fed the same diet but lacking the feed product.

An equine gastric health formulation that is operable to heal gastrointestinal disorders such as but not limited to ulcers, wherein the present invention further improves liver function and detoxification of the horse. The formulation of the present invention in a preferred embodiment is water based wherein fifty percent of the formulation is distilled water which is approximately five hundred milliliters. A concentration of one percent of the total solution is formed by origanum vulgare. Another two percent of the formula being represented equally is silybum marianum and taraxacum. Three drops of mentha piperita are also dispensed into the formulation of the present invention. Wherein the formulation includes ten percent of chlorophyllin and thirty seven percent is camelina oil. Additionally, four tablespoons of acacia gum powder are mixed into the formulation.

An equine gastric health formulation that is operable to heal gastrointestinal disorders such as but not limited to ulcers, wherein the present invention further improves liver function and detoxification of the horse. The formulation of the present invention in a preferred embodiment is water based wherein fifty percent of the formulation is distilled water which is approximately five hundred milliliters. A concentration of one percent of the total solution is formed by origanum vulgare. Another two percent of the formula being represented equally is silybum marianum and taraxacum. Three drops of mentha piperita are also dispensed into the formulation of the present invention. Wherein the formulation includes ten percent of chlorophyllin and thirty seven percent is camelina oil. Additionally, four tablespoons of acacia gum powder are mixed into the formulation.

Compositions are provided comprising a pro-reparative factor such as a colostrum, a nutritional protease inhibitor to decrease enzymatic digestion of the pro-reparative factors, and optionally a stabilizing agent, to allow the pro-reparative factors to reach the small intestine intact following oral administration. Methods are provided for treating, alleviating, and preventing inflammatory bowel disease (IBD) and other disorders of the gastrointestinal tract.

Compositions are provided comprising a pro-reparative factor such as a colostrum, a nutritional protease inhibitor to decrease enzymatic digestion of the pro-reparative factors, and optionally a stabilizing agent, to allow the pro-reparative factors to reach the small intestine intact following oral administration. Methods are provided for treating, alleviating, and preventing inflammatory bowel disease (IBD) and other disorders of the gastrointestinal tract.

Compositions are provided comprising a pro-reparative factor such as a colostrum, a nutritional protease inhibitor to decrease enzymatic digestion of the pro-reparative factors, and optionally a stabilizing agent, to allow the pro-reparative factors to reach the small intestine intact following oral administration. Methods are provided for treating, alleviating, and preventing inflammatory bowel disease (IBD) and other disorders of the gastrointestinal tract.